Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial
Chen et al., Frontiers in Pharmacology, doi:10.3389/fphar.2021.683296
https://c19early.org/chen4.html